Intellia Therapeutics Inc (NTLA) 今日盘中股价大幅上涨5.01%，引起了市场的广泛关注。
消息面上，美国食品药品监督管理局（FDA）已解除对其治疗心脏病的实验性基因疗法后期临床试验的临床搁置。这一监管进展为该公司关键药物的研发扫清了障碍，增强了市场对其未来前景的信心，从而推动了股价的上涨。
据悉，该基因编辑疗法名为nexiguran ziclumeran，旨在治疗转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）。去年，因一名患者出现严重的肝脏并发症，FDA暂停了相关试验。今年1月，FDA解除了对其中一项试验的搁置，而本次解除搁置涉及第二项试验，意味着该疗法的心脏病临床试验得以全面恢复。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.